Abstract
Anaplastic oligodendroglioma (AO) is rare in children. Treatment typically consists of varying combinations of surgery, chemotherapy, and radiotherapy. We present a pediatric case of frontal lobe AO with periventricular subcallosal extension and local leptomeningeal involvement. The isocitrate dehydrogenase (IDH) wild-type tumor was MGMT methylated and contained an ATRX mutation, BRAF alteration, and 1p/19q co-deletion; a combination of alterations mostly encountered in pediatric oligodendrogliomas. The patient underwent a near total resection and had a complete, durable response to temozolomide alone, suggesting that conservative management without radiation may be appropriate in some cases. We review the literature of this uncommon subtype of glioma in children.
| Original language | English |
|---|---|
| Article number | e26708 |
| Journal | Pediatric Blood and Cancer |
| Volume | 64 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 2017 |
Bibliographical note
Publisher Copyright:© 2017 Wiley Periodicals, Inc.
Funding
Gregory K. Friedman, Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham 1600 7th Ave South Lowder 512, Birmingham, AL 35233. Email: [email protected] Grant sponsor: National Institutes of Health Director’s Early Independence Award; Grant number: DP5 OD021403. This work was supported in part by the National Institutes of Health
| Funders | Funder number |
|---|---|
| National Institutes of Health (NIH) | DP5 OD021403 |
| Foundation for the National Institutes of Health |
Keywords
- 1p19q
- children
- codeletion
- oligodendroglioma
- pediatric
- temozolomide
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Hematology
- Oncology
Fingerprint
Dive into the research topics of 'Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver